Table 1 Baseline characteristics of all patients with IPAH

From: Sex-specific cardiopulmonary exercise testing parameters as predictors in patients with idiopathic pulmonary arterial hypertension

 

All patients

Male patients

Female patients

 

Eventa (n=24)

Eventa-free (n=33)

Eventa (n=9)

Eventa-free (n=12)

Eventa (n=15)

Eventa-free (n=21)

Clinical variables

 Age, y

38.3±16.1

40.7±13.0

43.9±22.0

41.6±13.8

34.9±10.8

40.2±12.8

 BMI, kg m−2

22.0±2.9

23.0±3.2

22.9±3.4

23.6±3.3

21.5±2.5

22.7±3.1

 WHO FC, n (%)

I–II

18 (75.0)

20 (60.6)

7 (77.8)

7 (58.3)

11 (73.3)

13 (61.9)

III–IV

6 (25.0)

13 (39.4)

2 (22.2)

5 (41.7)

4 (26.7)

8 (38.1)

 6 MWD, m

417.5±108.8

385.5±97.5

465.7±98.4

357.4±104.9

391.2±109.2

402.0±92.1

 NT pro-BNP, pg ml−1

665 (187, 1555)

182 (35, 639)b

796 (133, 2290)

91 (36, 489)

620 (219, 1516)

183 (34, 649)

Hemodynamics

 mRAP, mm Hg

6.0±3.9

5.4±4.7

7.6±4.4

6.0±5.7

5.33±3.3

4.9±4.0

 mPAP,mm Hg

57.9±11.5

53.2±13.5

60.3±10.8

53.0±14.1

57.8±12.4

53.0±13.0

 mPAWP,mm Hg

6.6±3.0

7.6±3.6

8.0±1.9

7.4±2.6

6.2±3.3

7.4±4.2

 PVR, Wood units

14.0±4.4

10.3±4.5*

14.3±4.2

10.0±4.7

14.7±4.3

10.3±4.5**

 CO, l min−1

2.9±0.5

3.0±0.6

3.9±0.9

4.9±1.7

3.9±0.9

4.7±1.1*

 SVO2, %

63.9±12.6

66.5±9.3

58.0±7.0

64.9±12.2

66.9±14.7

68.0±6.2

Specific medications

 PDE- 5 inhibitors, %

11 (45.8)

15 (45.5)

2 (22.2)

7 (58.4)

9 (60.0)

8 (38.1)

 ERAs, %

3 (12.5)

8 (24.2)

0 (0.0)

3 (25.0)

3 (20.0)

5 (23.8)

 Prostacyclin analog, %

0 (0.0)

3 (9.1)

0 (0.0)

1 (8.3)

0 (13.0)

2 (9.5)

Combination, %

9 (37.5)

6 (18.2)

7 (77.8)

1 (8.3)

2 (13.3)

5 (23.8)

 No specific medication

1 (4.2)

1 (3.0)

0 (0.0)

0 (0.0)

1 (6.7)

1 (4.8)

  1. Abbreviations: 6MWD, 6- min walk distance; BMI, body mass index; CO, cardiac output; ERAs, endothelial receptor antagonist; IPAH=idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; mPAWP, mean pulmonary capillary wedge pressure; mRAP, mean right atrial pressure; NT pro-BNP, N-terminal pro-brain natriuretic peptide; PDE-5, phosphodiesterase type 5; PVR, pulmonary vascular resistance; SVO2, mixed venous O2 saturation; WHO FC, World Health Organization functional class.
  2. aEvent defined as cardiopulmonary death, hospitalization for right heart failure, addition of another active therapy.
  3. *P<0.05 and **P<0.01, event -free vs. event.
  4. Values are mean (s.d.) or median (interquartile range) for clinical worsening or a switch from oral PAH-active therapy to parenteral for clinical worsening.
Back to article page